The Expression And Clinical Correlation Of The P2RY2 Gene In Acute Myeloid Leukemia

Objective: Acute myeloid leukemia(AML)is the most common type disease in acute leukemia.Most patients have short survival time,poor prognosis,and severely impaired quality of life.The occurrence and development of acute myeloid leukemia is a complex process with multiple factors and multiple steps,which is closely related to human molecular and cytogenetics.P2Y2 receptor(purinergic receptor P2 Y,G protein-coupled,2),the product of gene P2RY2,is widely expressed in a variety of tumor cells,and activates different downstream related signal transduction through interaction with inflammation and signaling factors in the tumor microenvironment.Pathway,it affects the proliferation and migration of tumor cells,is one of the potential targets of malignant tumor treatment.Its expression level and clinical significance in AML are still unclear.Methods: Real-time fluorescence quantitative RT-PCR was used to detect the expression of gene P2RY2 in 16 patients with non-malignant hematological disease and 89 newly diagnosed AML patients.Then further evaluate the correlation between the clinical characteristics,treatment response or prognosis of AML patients and the expression level of gene P2RY2.At the same time,149 AML patients in the TCGA database were selected to analyze the correlation between the gene P2RY2 and the clinical characteristics and prognosis of AML patients.Results: 1.The expression of gene P2RY2 in AML patients except acute promyelocytic leukemia(APL)is lower than that of patients with non-malignant hematological diseases(P=0.011);2.In AML patients witch except APL,the relatively high expression of gene P2RY2 is negatively correlated with the ratio of bone marrow blasts at first diagnosis(P=0.003);3.The expression of gene P2RY2 in AML patients with DNMT3 A,IDH2,TET2 gene mutations was lower than that in wild-type AML patients(P=0.047,0.034,0.013,0.008);4.In normal karyotypes AML patients the low expression of gene P2RY2 is related to the mutation of gene TET2(P=0.047);5.P2RY2 gene expression in patients with good prognosis in the AML prognosis risk stratification is lower than that of patients with intermediate prognosis(P=0.002);6.P2RY2 gene expression in patients with relatively high expression in AML has longer The overall survival(OS)than that in patients with relatively low expression(P=0.034).Conclusions: The gene of P2RY2 is low expressed in AML other than APL,and its low expression is related to the increase in the ratio of bone marrow blasts in AML patients and the mutation of DNMT3 A,IDH2,TET2 genes.The low expression of gene P2RY2 in normal karyotypes AML patients is related to the mutation of gene TET2.The prognosis of AML patients with low P2RY2 expression is poor.